Flexion Therapeutics (FLXN) – Company Press Releases
-
Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer
-
Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management
-
Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management
-
Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Meredith Corporation, Aspen Technology, Flexion, and Columbia Banking System on behalf of Stockholders and Enc
-
MERGER ALERT - ADMS, AZPN, and FLXN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
-
MERGER ALERT - ADMS, AZPN, and FLXN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
-
FLEXION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FLXN and Encourages Investors to Contact the Firm
-
MERGER ALERT - ADMS, AZPN, and FLXN: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
-
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
-
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
-
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
-
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference
-
Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee
-
Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain
-
Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA)
-
Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights
-
Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021
-
Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
-
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
-
Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer
-
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
-
Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare Conference
-
Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates
-
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Flexion Therapeutics to Report First-Quarter 2021 Financial Results on May 12, 2021
-
Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
-
Flexion Therapeutics Announces Preliminary First-Quarter 2021 Revenue and Provides Financial Guidance for 2021
-
Flexion Therapeutics to Present at the Needham 20th Annual Virtual Healthcare Conference
-
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Flexion Therapeutics Announces First Patient Treated in FX301 Phase 1b Trial for Management of Post-Operative Pain
-
Flexion Therapeutics to Present at the Oppenheimer 31st Annual Virtual Healthcare Conference
-
Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial Results
-
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2020 Financial Results on March 10, 2021
-
Flexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301, a Novel Formulation of a Locally Administered NaV1.7 Inhibitor for Post-Operative Pain
-
Flexion Therapeutics to Present at the 42nd Annual Raymond James Virtual Institutional Investors Conference
-
Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment Groups
-
National Basketball Retired Players Association, Sheryl Swoopes and Flexion Therapeutics Announce Partnership to Raise Awareness of ZILRETTA®
-
Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results
-
Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference
-
Flexion Therapeutics to Present at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference
-
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
-
Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights
-
Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020
Back to FLXN Stock Lookup
